Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Shares Issued (2017 - 2025)

Cytokinetics (CYTK) has disclosed Shares Issued for 14 consecutive years, with -$46.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued changed N/A to -$46.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$93.6 million, a N/A change, with the full-year FY2024 number at $53.0 million, up 187.21% from a year prior.
  • Shares Issued was -$46.5 million for Q4 2025 at Cytokinetics, down from -$3.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $93.6 million in Q1 2024 to a low of -$46.5 million in Q4 2025.
  • A 5-year average of $3.9 million and a median of $3.6 million in 2022 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 2539.98% in 2024; the steepest drop was 867.36% in 2024.
  • Cytokinetics' Shares Issued stood at $15.1 million in 2021, then tumbled by 76.24% to $3.6 million in 2022, then skyrocketed by 413.04% to $18.5 million in 2023, then plummeted by 118.77% to -$3.5 million in 2024, then tumbled by 1243.42% to -$46.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Shares Issued are -$46.5 million (Q4 2025), -$3.5 million (Q3 2024), and -$43.6 million (Q2 2024).